Anti-VEGF (Bevacizumab), humanized Antibody
Human Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| E |
---|---|
Primary Accession | AAP86646 |
Reactivity | Human |
Host | Human |
Clonality | Monoclonal |
Isotype | Human IgG1 |
Application & Usage | Neutralization: 0.1-20 µg/ml, ELISA: 2 µg/ml |
---|---|
Alias Symbol | VEGF |
Other Names | Avastin |
Appearance | Colourless liquid |
Formulation | 100 ug (2mg/ml) of antibody in Phosphate buffered saline, pH 7.4. |
Reconstitution & Storage | -20 °C |
Background Descriptions | |
Precautions | Anti-VEGF (Bevacizumab), humanized Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Bevacizumab (Avastin) is a recombinant humanized monoclonal IgG1 antibody. Bevacizumab, targets the cell surface protein called vascular endothelial growth factor (VEGF) results in suppression of tumor growth. VEGF plays an essential role in developmental angiogenesis and is also important for reproductive and bone angiogenesis. Avastin is used to treat various cancers like metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma and metastatic renal cell carcinoma.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.